The ELAD 2b study tested liraglutide in people with mild to moderate Alzheimer's disease. Liraglutide was safe and well tolerated over one year of administration. The results showed no significant slowing of cerebral metabolic decline compared to placebo. However, patients treated with liraglutide had a more pronounced slowing of brain volume loss, particularly in temporal and total brain gray matter. In cognitive tests, an 18% slower decline in cognitive function was observed in patients on liraglutide compared with placebo. The study was multicenter, randomized, double-blind, and included 204 patients. The primary objective of the study was not met, but significant secondary benefits for brain and cognition were observed.